The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma should only be initiated if the clinical evidence for the presence of tumor is reasonably ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Treatment for pheochromocytoma involves blood pressure medications followed by surgery, usually laparoscopic (minimally invasive) removal of one or both adrenal glands. Cushing’s syndrome is a ...